Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Researchers discover how brain cancer cells evade the body's immune system

Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body's immune system.

27 Aug 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

27 Aug 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Highly expressed protein in lung cancer cells drives resistance to targeted therapies

A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery.

25 Aug 2020

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

7 Aug 2020

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.

16 Jul 2020

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

9 Jul 2020

Researchers to receive Real-World Data Impact Award to advance patient-centric research

Three American Cancer Society researchers will receive the Real-World Data Impact Award to advance patient-centric research, the ACS and Flatiron Health announced today.

1 Jul 2020

Artificial neural network can provide information about lung cancer severity

Computed tomography (CT) is a major diagnostic tool for assessment of lung cancer in patients. Now NIBIB-funded researchers at Stanford University have created an artificial neural network that analyzes lung CT scans to provide information about lung cancer severity that can guide treatment options.

25 Jun 2020

ACCC releases preliminary results from survey on stage III and IV lung cancer care

The Association of Community Cancer Centers today released preliminary results and an initial set of quality care recommendations from Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC, an initiative to improve care delivery and outcomes for advanced non-small cell lung cancer (NSCLC) patients.

23 Jun 2020

Study highlights role of EGFR mutations in predicting recurrence in lung cancer

Volume 11, Issue 22 of @Oncotarget reported that while lobectomy can improve mortality in this group, about 30 55% of patients will experience disease recurrence.

10 Jun 2020

Study reveals outcomes of radiosurgery for patients with brain metastases from small cell lung cancer

The international First-line Radiosurgery for Small-Cell Lung Cancer analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery, without prior treatment with whole-brain radiation or prophylactic cranial irradiation.

5 Jun 2020

New analysis supports first-line stereotactic radiosurgery for small cell lung cancer

The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery (SRS), without prior treatment with whole-brain radiation (WBRT) or prophylactic cranial irradiation (PCI).

5 Jun 2020

A moving target identified in small cell lung tumors

Lung cancers account for approximately 25 percent of all cancer deaths. Even among those who do not smoke, 1 in 15 men and 1 in 17 women are expected to develop lung cancer in their lifetime, according to the American Cancer Society.

1 Jun 2020

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System.

30 May 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology Annual Meeting ASCO20 Virtual Meeting (Abstract 9556 - Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.

29 May 2020

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Small Cell Lung Cancer News and Research

Researchers discover how brain cancer cells evade the body's immune system

New diagnostic tool can predict cancer patients' response to immunotherapy

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

Highly expressed protein in lung cancer cells drives resistance to targeted therapies

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

Researchers to receive Real-World Data Impact Award to advance patient-centric research

Artificial neural network can provide information about lung cancer severity

ACCC releases preliminary results from survey on stage III and IV lung cancer care

Study highlights role of EGFR mutations in predicting recurrence in lung cancer

Study reveals outcomes of radiosurgery for patients with brain metastases from small cell lung cancer

New analysis supports first-line stereotactic radiosurgery for small cell lung cancer

A moving target identified in small cell lung tumors

New immunotherapy for metastatic non-small cell lung cancer shows promise in clinical trial

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

Targeted therapy tepotinib shows durable response in NSCLC patients with METex14 skipping mutation

Targeted therapy pralsetinib shows high response rates in patients with RET fusion-positive cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News